RSV MAT-004: A Phase II observer-blind study to assess safety, reactogenicity, and immunogenicity of GSK Biologicals’ investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women and infants born to vaccinated mothers

Project Details

StatusActive
Effective start/end date11/11/1930/04/20

Funding

  • GlaxoSmithKline